Sign in Subscribe
Cancer

Epstein-Barr Virus Linked to Gastric Cancer Through Apoptosis Suppression

Strategic Insights

— 1 min read

Research at Chiba University, Japan, has established a connection between Epstein-Barr Virus (EBV) and gastric cancer through the suppression of apoptosis. The study, published in The Journal of Pathology, found that EBV-positive gastric cancers (GCs) exhibit unique carcinogenic pathways that evade apoptosis in the absence of TP53 mutation. The research suggests that these cases may be responsive to therapeutic strategies that target the p53 pathway.

Key Takeaways:

  • The study identified four DNA methylation epigenotypes (MEs) in GCs, including high ME (HME), extremely HME (E-HME), low ME (LME), and extremely LME (E-LME).
  • E-HME was found to match EBV-positive GC (E-HME/EBV), and HME can be further categorized into MLH1-deficient (HME_MLH1(-)) and proficient cases.
  • The Cancer Genome Atlas data confirmed that HME_MLH1(-)/microsatellite instability (MSI) and E-HME/EBV cases retain TP53_WT and have higher MDM2 expression levels than other MEs.
  • Short hairpin RNA-mediated MDM2 knockdown and p53-MDM2 inhibitors, nutlin-3 and RG7388, induced apoptosis in TP53_WT GC cells, indicating that activated MDM2 suppresses p53 protein levels and attenuates the downstream p53 pathway activation.
  • The research concludes that DNA-hypermethylated GC cases, HME_MLH1(-)/MSI and E-HME/EBV, follow a unique carcinogenic pathway to evade apoptosis in the absence of TP53 mutation, potentially making them responsive to therapeutic strategies that function primarily through the p53 pathway.

Statistics:

  • 50% of the gastric cancers (GCs) remain wildtype TP53 (TP53_WT).
  • 4 DNA methylation epigenotypes (MEs) were identified in GCs: high ME (HME), extremely HME (E-HME), low ME (LME), and extremely LME (E-LME).
  • 2 p53-MDM2 inhibitors, nutlin-3 and RG7388, were used to induce apoptosis in TP53_WT GC cells.

Sources:

  • Research publication: DNA-hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation. The Journal of Pathology, 2025.
  • Funding organizations: Japan Agency for Medical Research and Development, Chiba University, Japan Society for the Promotion of Science.
  • Authors: Keisuke Matsusaka, Yasunobu Mano, Motoaki Seki, Kazuko Kita, Masaki Fukuyo, Bahityar Rahmutulla, Genki Usui, Ryoji Fujiki, Masayuki Urabe, Hiroyuki Abe, Hisahiro Matsubara, Tetsuo Ushiku, Yasuyuki Seto, Masashi Fukayama, and Atsushi Kaneda.
  • Publisher: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Read more